Business Context and Reporting Period
This Form 8-K Current Report was filed by MIRA Pharmaceuticals, Inc. on November 18, 2024. The filing addresses corporate governance changes under Item 5.02, specifically the resignation of a director and the appointment of a new director to the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Michael Jerman resigned from the Board of Directors and his role as Chair of the Audit Committee, effective immediately on November 18, 2024. The resignation was due to his desire to pursue other activities and was not related to any disagreement with the Company.
- Appointment: Matthew Pratt Whalen was appointed as a member of the Board and Chairman of the Audit Committee, effective November 18, 2024.
Outlook, Risks, and Management Commentary
Management highlighted Mr. Whalen's qualifications, noting his status as a Certified Public Accountant (CPA) with over two decades of experience in public accounting and corporate finance. His recent roles include CFO of Power Digital Marketing Inc. and a director at Telmoir Pharmaceuticals, Inc. The filing states there are no undisclosed arrangements regarding his selection and no reportable transactions between the Company and the new director. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the effective date of the Board composition change (November 18, 2024).
- Confirm the new Audit Committee Chair's background and potential conflicts of interest via his other board roles (e.g., Telmoir Pharmaceuticals).
- Review subsequent filings for any impact on the Company's financial reporting or audit processes following the leadership transition.